Is multidisciplinary management possible in the treatment of lung cancer? A report from three Italian meetings
- 27 Downloads
To report criticisms and barriers to the “real-life” application of international guidelines and recent developments in the management of locally advanced non-small cell lung cancer (NSCLC) in Italy.
Three 2-day courses were organized. During the first day, experts in different fields of thoracic oncology gave their lecture on diagnosis and therapy for locally advanced NSCLC. During the second day, all participants were divided into four groups to discuss on a clinical case as a multidisciplinary team (MDT). The aim was to stimulate the discussion on practical issues in the management of NSCLC patients in the real-life practice.
A total of 196 physicians were involved in the courses as learners. Invasive diagnosis of nodal disease for staging purposes, a priori definition of “surgical resectability” and a regular MDT with all crucial participants available were the three main key points identified for a good management of these patients. The main barriers to the clinical application of a good diagnostic and therapeutic approach to the patient were the absence of a regular and complete MDT in the South and Centre of Italy, while in the North of Italy, time for discussion of clinical cases in the MDT and waiting lists for staging and therapeutic interventions were deemed as the major concerns.
The meetings showed that diagnosis and treatment of locally advanced NSCLC are still extremely variable between different Italian regions. Logistic issues, waiting lists, paucity of well-trained staff and expertise seem to be the main barriers to international guidelines application.
KeywordsNon small cell lung cancer Stage III Multidisciplinary evaluation
Compliance with ethical standards
Conflict of interest
Dr Alessio Bruni-Astra Zeneca: Support for Conference participation, Advisory board. All other authors declare no conflict of interest.
Research involving human participants and/or animals
- 1.Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin D, Forman D, Bray F (2013) GLOBOCAN 2012 v1.0, cancer incidence and mortality worldwide: IARC cancerbase No. 11. International Agency for Research on CancerGoogle Scholar
- 4.NCCN guidelines version 2.2019 Non small cell lung cancerGoogle Scholar
- 5.Postmus PE, Kerr KM, Oudkerk M, Senan S, Waller DA, Vansteenkiste J, Escriu C, Peters S, ESMO Guidelines Committee (2017) Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 28(Suppl 4):iv1–iv21. https://doi.org/10.1093/annonc/mdx222 CrossRefPubMedGoogle Scholar
- 6.Bruni A, Grossi F, Ferrari K et al (2018) The standard of care for stage III NSCLC in the era of immunotherapy: An Italian national survey on the current pattern of care among Italian thoracic oncologists. Ann Oncol 29(suppl 8):291-013Google Scholar
- 7.Lipmanowicz H, McCandless K (2014) The surprising power of liberating structures: simple rules to unleash a culture of innovation. Liberating Structures Press, SeattleGoogle Scholar
- 12.Kim SH, Lee JH, Lee GJ (2015) Interpretation and prognostic value of positron emission tomography-computed tomography after induction chemotherapy with or without radiation in IIIA-N2 non-small cell lung cancer patients who receive curative surgery. Medicine (Baltimore) 94(24):e955CrossRefGoogle Scholar
- 18.Hurria A, Wildes T, Blair SL et al (2018) Senior adult oncology, version 2.2014: clinical practice guidelines in oncology. Elderly patients with advanced NSCLC: The value of geriatric evaluation and the feasibility of CGA alternatives in predicting chemotherapy toxicity. PulmonologyGoogle Scholar